“Drug of last resort” vs. “broad use”
- crucial distinction because impacts overall drug development plan
- has activity but would be “restricted” for use only in H.T.E. because of toxicity, route of administration or other reasons
- in contrast to a first-in-class or next-in-class that can be used for both early rx or for H.T.E.